Detailed Explanation
A synthetic molecule designed to mimic the biological activity of a natural peptide while improving pharmacological properties — typically oral bioavailability, metabolic stability, and cell permeability. Peptidomimetics retain the key pharmacophore (the minimal structural features needed for receptor binding) but replace the peptide backbone with non-peptidic scaffolds that resist protease degradation.
Strategies include backbone modification (N-methylation, peptoids, β-peptides, azapeptides), conformational constraints (cyclization, stapling), and complete scaffold replacement with small-molecule mimics. Successful peptidomimetic drugs include the HIV protease inhibitors (saquinavir, ritonavir, lopinavir) and the DPP-IV inhibitors (sitagliptin, saxagliptin) — both classes were designed by mimicking the transition state of peptide substrates.
Key Facts
- A synthetic molecule designed to mimic the biological activity of a natural peptide while improving pharmacological properties — typically oral bioavailability, metabolic stability, and cell permeability.
- Peptidomimetics retain the key pharmacophore (the minimal structural features needed for receptor binding) but replace the peptide backbone with non-peptidic scaffolds that resist protease degradation.
- Strategies include backbone modification (N-methylation, peptoids, β-peptides, azapeptides), conformational constraints (cyclization, stapling), and complete scaffold replacement with small-molecule mimics.
- Successful peptidomimetic drugs include the HIV protease inhibitors (saquinavir, ritonavir, lopinavir) and the DPP-IV inhibitors (sitagliptin, saxagliptin) — both classes were designed by mimicking the transition state of peptide substrates.
Part of the PeptideBond.com education network
Educational Disclaimer
PeptideDefinition.com provides educational content about peptide science. Not medical advice. Consult a licensed healthcare provider for medical decisions.